Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026
PR Newswire•14/10/2026•07:00 ET
0
Key Highlights
- ➤Insmed will present three late-breaking TPIP abstracts at CHEST 2026.
- ➤TPIP data span pulmonary arterial hypertension and PH-ILD development programs.
- ➤BRINSUPRI ASPEN analysis links patient-reported sputum color with proteases and exacerbations.
- ➤ARIKAYCE ENCORE findings examine amikacin and macrolide resistance in newly diagnosed MAC lung disease.
Expert Statements
Martina Flammer, Chief Medical Officer of Insmed
“This fall medical congress season is a powerful reminder of what's possible when we stay focused on delivering meaningful solutions for patients who need them most.”
Martina Flammer, Chief Medical Officer of Insmed
“From CHEST 2026 to IDWeek 2026, we're proud to share data across our respiratory portfolio, including BRINSUPRI, TPIP, and ARIKAYCE.”
Martina Flammer, Chief Medical Officer of Insmed
“Altogether, these presentations reflect the strength and diversity of our growing respiratory portfolio and our unwavering dedication to advancing critical therapies that have the potential to benefit the patients we aim to serve.”
Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026 PR Newswire
—Three Late-Breaking Abstracts at CHEST 2026 Deepen Understanding of the Potential of Treprostinil Palmitil Inhalation Powder (TPIP) Across Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)—
Get started
Create a free account to read the full story.